Add to Watchlist Create Alerts

Real-Time Last Update

Last Sale Cboe BZX Real-Time

Volume

Quest Diagnostics Elects Luis A. Diaz, Jr., M.D. to its Board, Expanding the Number of Directors to 10

PR Newswire - Wed May 17, 2023

SECAUCUS, N.J., May 17, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors has elected Luis A. Diaz, Jr., M.D. to serve as a director. Including Dr. Diaz, the company's Board has 10 members.

Dr. Diaz, 52, has been Head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center since December 2016. Previously, he was a faculty member and physician at the Johns Hopkins University School of Medicine. He has founded several biotechnology companies, including Epitope, Inostics, PapGene (Thrive) and Personal Genome Diagnostics, Inc.

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

The close: Stocks higher as investors focus on Fed moves

The close: Major North American indexes rise as megacap tech stocks rally

Why this money manager is venturing back into emerging markets and adding more U.S. tech

How a Canadian pirate-clad pastor helped ignite Trump Media’s market frenzy

report on business

Activist investor targets Dye & Durham’s ‘underperformance and strategic missteps’ in letter to shareholders

The close: U.S. stocks fall as GDP report spreads rate-cut gloom; Alphabet surges 15% in post market

report on business

Fiera Capital’s largest shareholder looks to sell stake in company

The close: S&P 500 higher as markets weigh rising bond yields and upbeat U.S. earnings; TSX lower as rails slide